Glioma Panel – Advance
The Glioma Panel – Advance tests for advanced genetic markers and mutations in gliomas, including IDH1/2, MGMT promoter methylation, and other molecular alterations. This test provides detailed information about the glioma’s molecular profile, guiding treatment decisions and prognosis. It helps tailor personalized therapy for glioma patients.
Glioma Panel – Advance Package in New Delhi Overview
What is Glioma Panel – Advance (EGFR & 1P AND 19Q) test?
A combined assay that evaluates EGFR (commonly amplification and selected mutations/variant III) and detects 1p/19q whole‑arm codeletion, reported within an integrated neuro‑oncology workup. Results help establish lineage: 1p/19q codeletion supports oligodendroglioma when paired with IDH mutation. EGFR amplification is a hallmark feature of IDH‑wildtype glioblastoma and is generally mutually exclusive with true whole‑arm 1p/19q codeletion.
Why consider Glioma Panel – Advance (EGFR & 1P AND 19Q) test?
- Improves diagnostic confidence when histology is limited or equivocal by capturing two pivotal copy‑number signatures that steer classification and grade assignment.
- Guides treatment decisions: EGFR amplification may inform eligibility for EGFR‑targeted strategies/clinical trials, whereas confirmed 1p/19q codeletion predicts chemosensitivity and better outcomes in oligodendroglioma.
Who should get tested for Glioma Panel – Advance (EGFR & 1P AND 19Q) test?
- Patients with newly diagnosed diffuse gliomas in whom distinguishing oligodendroglial lineage from IDH‑wildtype glioblastoma would change management.
- Cases with small biopsies or conflicting findings where EGFR status and 1p/19q copy‑number clarify diagnosis and prognosis, or recurrent disease where re‑profiling may open targeted trial options.
More Information about Glioma Panel – Advance (EGFR & 1P AND 19Q) test
OTHER NAMES: Advanced Glioma Copy‑Number Panel (EGFR + 1p/19q), EGFR amplification with 1p/19q assessment (FISH/NGS), Glioma Advanced Marker Panel (EGFR and 1p/19q)
Glioma is a primary tumor of glial cells in the brain and spinal cord, now classified primarily by molecular markers alongside histology, especially IDH mutation status and 1p/19q codeletion in adults. Modern classification separates adult diffuse gliomas into IDH‑mutant astrocytoma, IDH‑mutant and 1p/19q‑codeleted oligodendroglioma, and IDH‑wildtype glioblastoma, which differ in prognosis and therapy response.
No special preparations needed
- Request Letter
- Clinical Indications
- Block Id No.
- Specimen
- Time Of Fixation
- Duration Of Fixation
- Number Of Observers
- Total Number Of Cells Counted (a)
- Average Egfr (orange) Signals Counted/ Nucleus (b)
- Average Cep 7 (green) Signals Counted/ Nucleus (c)
- Ratio Of Average Egfr Signals/ Average Cep 7 Signals (b/c)
- Interpretation
- Request Letter
- Specimen
- Block Indentification Number
- Number Of Observers
- Total Number Of Cells Analysed
- Deletion 1p
- Loss Of Chromosome 1
- Normal
- Interpretation (1p)
- Total Number Of Cells Analysed
- Deletion 19
- Loss Of Chromosome 19
- Normal
- Interpretation (19q)
- Interpretation
- Mgmt Promoter Methylation
- Idh1 And Idh2 Gene Mutation Detection
- Tert C228t And C250t Mutation
Test code
1835
Specimen vol. and vacutainer information
| Specimen | Vacutainer | Volume |
|---|---|---|
| Blocks | Others | 1 |
| Edta Whole Blood | Lavender Vacutainer | 2 ML |
| Paraffin Block | Others | 6 NOS |
| Plasma Cit.frozen | Blue Vacutainer | 1 ML |
Specimen stability information
Paraffin Block
Collection instructions
Age,Gender,Clinical history required
Specimen rejection criteria
Test run frequency
'
Turn around time
10 Working Days
Performing locations
Department
- Advanced Molecular Diagnostics R&d
- Cytogenetics
CPT and Loinc codes
Package price
₹31000
Need Help?
Talk to our health experts for guidance on tests, reports, or bookings.
WhatsApp to Book TestGlioma Panel – Advance
₹31000